MindWalk Holdings Q1 Fiscal 2027 Earnings: Revenue Rises to C$3.8 Million

Quick Verdict

MindWalk Holdings reported fiscal Q1 2027 revenue of C$3.8 million, up 21.3% year over year, and a continuing-operations loss of C$0.13 per share. Gross margin rose to 58.6%, but investment in ReefIQ commercialization widened the loss. Shares traded modestly higher intraday, with after-hours movement not reported.

About MindWalk Holdings

MindWalk Holdings Corp. (NASDAQ: HYFT) is an Austin, Texas-based Bio-Native AI company that combines AI, curated biological data and advanced wet-lab capabilities for drug discovery and life-sciences applications. The company’s core HYFT technology represents biology through a proprietary database of 660 million patterns and 25 billion relationships, supporting its ReefIQ biological-data platform and LensAI discovery and reasoning tools. MindWalk said it serves 19 of the world’s 20 largest pharmaceutical companies through its discovery business and is seeking to shift commercial relationships toward larger, recurring platform agreements.

The company was incorporated in 1983 and had a market capitalization of roughly US$61 million–US$62 million around September 14, 2026, based on market-data providers. Because MindWalk remains loss-making, it does not have a meaningful conventional P/E ratio, and it does not report a dividend yield. HYFT traded around US$1.32 during the September 14 session.

Top Financial Highlights

1. Fiscal Q1 2027 revenue increased 21.3% year over year to C$3.834 million, from C$3.161 million
2. Gross profit grew 47.1% to C$2.246 million, from C$1.527 million
3. Gross margin expanded by 10.3 percentage points to 58.6%, from 48.3%
4. Cost of sales declined to C$1.588 million, compared with C$1.634 million a year earlier, enabling margin expansion
5. Net loss from continuing operations widened to C$6.085 million, versus C$4.088 million
6. Loss per share from continuing operations was C$0.13, compared with C$0.09 in the prior-year period
7. Total net loss was C$6.085 million, compared with C$2.959 million; the earlier period included C$1.129 million of discontinued-operations income
8. Total operating expenses rose 47.3% to C$8.375 million, from C$5.686 million
9. Sales and marketing expense increased to C$3.196 million from C$1.343 million, primarily for ReefIQ commercialization and enterprise sales infrastructure
10. General and administrative expense was C$3.894 million, up from C$3.294 million, mainly reflecting non-cash stock-based compensation
11. Research and development expense grew to C$1.285 million from C$1.049 million as the company added engineering capacity
12. Net cash used in operating activities improved slightly to C$4.042 million, versus C$4.213 million
13. Cash on hand was C$7.623 million at July 31, 2026, down from C$11.348 million at April 30, 2026
14. MindWalk announced a binding commitment for a revolving credit facility of up to US$30 million at a fixed 7.00% rate; amounts would be drawn only as needed, subject to completion of definitive documentation
15. About 80% of the commercial funnel by value is now in partnership-structured engagements, rather than discrete projects

Beat or Miss?

MindWalk’s earnings release did not disclose consensus analyst revenue or EPS estimates. Therefore, a formal earnings “beat” or “miss” cannot be established from company-released figures alone. Operationally, the report was mixed: revenue and gross margin rose materially, while the company posted a deeper net loss due to planned commercial, sales, and product-development spending.

The central investment question is whether ReefIQ enterprise negotiations can convert into contracted, recurring revenue rapidly enough to offset the current cost base. Management cautioned that early ReefIQ contracts may create uneven, milestone-driven revenue before developing into annual recurring revenue.

What Leadership Is Saying

President and Chief Executive Officer Jennifer Bath emphasized that the company is positioning ReefIQ as the center of a broader platform-based revenue model rather than merely an incremental software product.

“We delivered a strong quarter, with revenue up 21% and gross margin expanding to 59%, while launching ReefIQ into a market moving toward exactly what we built.” — Jennifer Bath, PhD, President and Chief Executive Officer

“Our commercial model is shifting to recurring, compounding revenue with ReefIQ at its center, and this gives us the balance sheet to make that shift on our own terms.” — Jennifer Bath, PhD, President and Chief Executive Officer

Chief Financial Officer Scott Areglado did not provide a direct quote in the formal earnings release. In the earnings-call coverage, he characterized the timing of initial ReefIQ arrangements as uncertain because early enterprise deployments can include engineering work and milestone payments before recurring annual revenue begins.

“These initial ReefIQ agreements are probably going to be relatively lumpy. It really just depends on how quickly we get adoption of ReefIQ.” — Scott Areglado, Chief Financial Officer

Historical Performance

All financial figures below are in Canadian dollars and compare the quarter ended July 31, 2026, with the quarter ended July 31, 2025.

The key positive in the period was operating leverage at the gross-profit level: revenue rose by C$0.673 million while cost of sales fell by C$0.046 million. However, this gain was more than offset by an approximately C$2.689 million rise in operating expenses, led by sales and marketing.

Competitor Comparison

A direct competitor table cannot be prepared on a like-for-like basis from the MindWalk release because it does not identify a peer group, disclose competitors’ contemporaneous financial results, or provide standardized peer revenue, profitability, and expense data. MindWalk operates across bio-AI, biological-data infrastructure, AI-enabled drug discovery, wet-lab biologics services, and platform partnerships—areas with different business models and reporting periods.

For positioning context, the company is attempting to differentiate through its integration of wet-lab biologics work, its HYFT biological representation layer, and ReefIQ/LensAI software infrastructure. This distinction matters because enterprise-platform deals may be larger and more recurring than conventional discovery-services contracts, but could have longer sales cycles and volatile early-stage revenue timing.

How the Market Reacted?

HYFT traded around US$1.32 on September 14, 2026, modestly above the prior close according to market-data snapshots, with intraday gains reported in the roughly 1%–2% range. The company’s earnings release itself did not provide an after-hours price reaction, so a definitive post-release move cannot be confirmed from the announcement.

Market sentiment was cautiously constructive rather than unequivocally bullish. Investors received evidence of revenue growth, substantial gross-margin expansion and potential non-dilutive financing flexibility, but must weigh those positives against a wider net loss, elevated operating expenses, declining quarter-end cash, and uncertainty over the timing and size of ReefIQ enterprise contracts. The US$30 million revolving-facility commitment is strategically important, although it remains subject to the negotiation and execution of definitive credit documentation.